Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
15 Novembro 2022 - 8:05AM
Edgar (US Regulatory)
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
Commission File Number: 333-156091
Notification of Late Filing
(Check One):
[ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR
For Period Ended: September 30, 2022
[ ] |
Transition Report on Form 10-K |
[ ] |
Transition Report on Form 20-F |
[ ] |
Transition Report on Form 11-K |
[ ] |
Transition Report on Form 10-Q |
[ ] |
Transition Report on Form N-SAR |
For the Transition Period Ended:
Nothing in this form shall be construed to imply that
the Commission has verified any information contained herein.
If the notification relates to a portion of the filing
checked above, identify the Item(s) to which the notification relates:
Part I - Registrant Information
Alterola Biotech,
Inc.
Full Name of Registrant |
__________________________ |
Former Name if Applicable |
47 Hamilton Square |
Address of Principal Executive Office (Street and Number) |
Birkenhead Merseyside United Kingdom
CH41 5AR |
City, State and Zip Code |
Part II - Rules 12b-25(b) and (c)
If the subject report could not be filed without unreasonable
effort or expense and the registrant seeks relief pursuant to Rule 12b-(b), the following should be completed. (Check box, if appropriate)
[X] (a) The reasons described in reasonable
detail in Part III of this form could not be eliminated without unreasonable effort or expense;
[X] (b) The subject annual report, semi-annual
report, transition report on Form 10-K, Form 20-F, 11-K or Form N- SAR, or portion thereof will be filed on or before the fifteenth calendar
day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed
on or before the fifth calendar day following the prescribed due date; and
[ ] (c) The accountant's statement
or other exhibit required by Rule 12b-25(c) has been attached if applicable.
Part III - Narrative
State below in reasonable detail the reasons why Form
10-K, 20-F, 11-K, 10-Q, N-SAR, or the transition report or portion thereof could not be file within the prescribed period.
The Company was unable to compile the necessary
financial information required with its accountants and the auditor’s review to prepare a complete filing. Thus, the Company would
be unable to file the periodic report in a timely manner without unreasonable effort or expense. The Company expects to file within the
extension period.
Part IV - Other Information
(1) Name and telephone number of person to contract
in regard to this notification.
David Hitchcock |
+44 151 601 9477 |
(Name) |
(Phone) |
(2) Have all other periodic reports required under
section 13 or 15(d) of the Securities Exchange Act of 1934 or section 30 of the Investment Company Act of 1940 during the preceding 12
months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).
[X] Yes [ ] No
(3) Is it anticipated that any significant change
in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included
in the subject report or portion thereof? [ ] Yes [X] No
If so: attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
Alterola Biotech, Inc.
(Name of Registrant as specified in charter)
has caused this notification to be signed on its behalf
by the undersigned thereunto duly authorized.
Date: August 14, 2022 |
By:
/s/ David Hitchcock |
|
David Hitchcock
Its: Chief Executive Officer |
Alterola Biotech (PK) (USOTC:ABTI)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Alterola Biotech (PK) (USOTC:ABTI)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024